Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Tenchusatsu who wrote (211371)	11/10/2004 12:49:34 PM
From: Alighieri	Read Replies (2) \| Respond to of 1571040

Al, there was nothing in that article about generics. Like I said before, importing drugs only makes sense for generic brands, not the new drugs you see advertised on TV. I don't think that's the case. Generics are developed for drugs for which patents have expired. They are considerably cheaper in the US as they are in Canada. Brand drugs in Canada are cheaper for two reasons... 1) Canada negotiates with drug companies to keep price lower 2) Canada controls end user pricing through subsidies. I am sure subsidies would not survive if the US allowed re-importation, so it means that the market would stabilize on pricing negotiated with drug companies in both Canada and the US. The effect would probably be lower profits for drug cos, but not hugely lower. The article alludes to that, which is why I posted it. The safety issue is a smokescreen. Al